title: Effects of serotonin 1A agonist on acute spinal cord injury.
abstract: METHODS
  We evaluated the effects of serotonin (5-HT) agonists on in vitro models of spinal cord compressive injury. Evoked potentials in injured rat spinal cords (n=24) were recorded during perfusion with 5-HT agonists.
  
  
  OBJECTIVE
  To evaluate the therapeutic effects of 5-HT agonists on the recovery of compound action potentials in injured spinal cords.
  
  
  METHODS
  Rat dorsal columns were isolated, placed in a chamber, and injured by extradural compression with a clip. Conducting action potentials were activated by supramaximal constant current electrical stimuli and recorded during perfusion with 5-HT agonists and antagonists.
  
  
  RESULTS
  After inducing compression injuries, mean action potential amplitudes were reduced to 33.9+/-5.4% of the pre-injury level. After 120 min of perfusion with Ringer's solution, the mean amplitudes recovered to 62.8+/-8.4% of the pre-injury level. At a concentration of 100 micro M, perfusion with tandospirone (a 5-HT1A agonist) resulted in a significantly greater recovery of mean action potential amplitudes at 2 h after the injury (86.2+/-6.9% of pre-injury value) as compared with the control Ringer's solution (62.8+/-8.4% of pre-injury value, P<0.05). In contrast, quipazine (a 5-HT2A agonist) accelerated the decrease of amplitude (54.5+/-11.7% of pre-injury value). 5-HT1A and 5-HT2A agonist did not consistently alter latencies of the action potentials.
  
  
  CONCLUSIONS
  The 5-HT1A receptor agonist was effective for the recovery of spinal action potential amplitudes in a rat spinal cord injury model.
authors.affiliation: Department of Orthopedic Surgery, Shiga University of Medical Science, Otsu, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Saruhashi
authors.forename: Y
authors.initials: Y
authors.lastname: Matsusue
authors.forename: S
authors.initials: S
authors.lastname: Hukuda
mesh_terms: D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000704:Analysis of Variance; D000818:Animals; D066298:In Vitro Techniques; D054833:Isoindoles; D008297:Male; D008803:Mianserin / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D011814:Quipazine / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D044402:Receptor, Serotonin, 5-HT2A; D011985:Receptors, Serotonin / Q000187:drug effects* / Q000502:physiology; D044263:Receptors, Serotonin, 5-HT1; D012702:Serotonin Antagonists / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology*; D013119:Spinal Cord Injuries / Q000188:drug therapy / Q000503:physiopathology*
chemical_list: D054833:Isoindoles; D010879:Piperazines; D011743:Pyrimidines; D044402:Receptor, Serotonin, 5-HT2A; D011985:Receptors, Serotonin; D044263:Receptors, Serotonin, 5-HT1; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; C055267:tandospirone; D008803:Mianserin; D011814:Quipazine